In a clinical study, FORTEO helped stimulate new bone with mineral properties consistent with younger bone age*10
FORTEO treatment increased the amount of newly formed bone matrix with lower, more heterogeneous mineral content (blue arrows), a property consistent with younger bone age.*
*Younger bone age is characterized by newly formed bone matrix with lower, more heterogeneous bone mineral content.
Analysis of mineralization at the tissue level shows that FORTEO promotes ongoing formation of new bone
FORTEO Select Safety Information
Transient orthostatic hypotension may occur with initial doses of FORTEO. FORTEO should be administered initially under circumstances in which the patient can sit or lie down if symptoms of orthostatic hypotension occur. In short-term clinical pharmacology studies of FORTEO in healthy volunteers, transient episodes of symptomatic orthostatic hypotension were observed in 5% of volunteers.
2. FORTEO Prescribing Information, 3. Riggs BL, Parfitt AM. J Bone Miner Res. 2005;20:177-184., 4. Raggatt LJ, Partridge NC. J Biol Chem. 2010;285:25103-25108., 5. Seeman E. Rheumatology (Oxford). 2008;47:iv2-iv8., 6. Dempster DW, et al. J Clin Endocrinol Metab. 2016;101:1353-1363., 7. Dempster DW, et al. J Bone Miner Res. 2016;31:1429-1439., 8. Dempster D, et al. J Clin Endocrinol Metab. 2012;97(8):2799-2808., 9. Data on file, Lilly Research Laboratories (FOR20161208A)., 10. Dempster DW, et al. J Bone Miner Res. 2016; 31(8):1527-1535.